3,973 reports of this reaction
3.7% of all METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS reports
#2 most reported adverse reaction
DIARRHOEA is the #2 most commonly reported adverse reaction for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, manufactured by AiPing Pharmaceutical, Inc.. There are 3,973 FDA adverse event reports linking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS to DIARRHOEA. This represents approximately 3.7% of all 106,995 adverse event reports for this drug.
Patients taking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 3,973 FDA reports for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.7% of all adverse event reports for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.